HOME >> BIOLOGY >> NEWS
Joslin Diabetes Center scientists find genetic defects

BOSTON -- Scientists at Joslin Diabetes Center have found genetic regions that, when defective, allow the immune system to attack the pancreas -- the first in a series of mis-steps that lead to type 1 diabetes. Armed with these findings, published today, March 22, in the journal Immunity, the researchers are now trying to hone in on the exact genes involved, in mice and in human patients.

"The significance of this study is that we found the chromosomal regions involved and can now zero in on the precise genes," said Diane Mathis, Ph.D., the study's principal investigator along with Christophe Benoist, M.D., Ph.D. They head the Section on Immunology and Immunogenetics at Joslin, and hold joint William T. Young Chairs in Diabetes Research. They are also Professors of Medicine at Harvard Medical School. The work was spearheaded by a group of Joslin fellows, hailing from across the globe: Silvia Zucchelli, Ph.D., who has now returned to Italy; Phil Holler, Ph.D., from the U.S.; and Tetsuya Yamagata, M.D., Ph.D, from Japan.

The genetic defect keeps the body from properly dealing with "errant" immune cells that it normally eliminates by a process called immunological tolerance. These immune cells then attack the insulin-producing beta cells in the pancreas, mistaking them as foreign invaders.

"It's critical for the immune system to recognize and tolerate tissues that belong in the body, which immunologists call 'tolerance,'" said Dr. Zucchelli. "Previous studies have shown that when the T-cells don't learn this tolerance, they can infiltrate the pancreas and attack the insulin-producing beta cells." This first step in the onset of type 1 diabetes is called insulitis. Later in life, within weeks or even years, full-blown type 1 diabetes emerges.

An estimated 1 million people in the United States have type 1 diabetes. Their pancreatic beta cells can no longer make insulin. Without this crucial hormone, their body cannot convert food into energy. To s
'"/>

Contact: Marjorie Dwyer
marjorie.dwyer@joslin.harvard.edu
617-732-2415
Joslin Diabetes Center
22-Mar-2005


Page: 1 2 3

Related biology news :

1. Joslin study indicates insulin receptors play a critical role in promoting islet growth
2. Joslin researchers discover a surprising culprit in the search for causes of diabetic birth defects
3. Joslin study reveals how a specific fat type can protect against weight gain and diabetes
4. Joslin discovers protein that causes blood vessel leakage and swelling with diabetic retinopathy
5. Joslin-led study uncovers role of appetite hormone MCH in insulin production
6. Joslin Diabetes Center study examines insulin pump therapy in adolescents
7. Joslin Diabetes Center in Boston establishes first affiliate in Canada
8. Walgreens and Joslin Diabetes Center form broad alliance to improve diabetes outcomes
9. Joslin awards Victory Medal to New York man living 75 years with type 1 diabetes
10. Joslins new book demystifies nutrition and meal planning for people with diabetes
11. Joslin study refutes recent report that bone marrow can replenish female oocytes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... April 20, 2017  Eli Lilly and Company (NYSE: ... evaluating galcanezumab for the prevention of migraine at the ... take place April 22-28, 2017, in Boston ... abstracts at AAN, including safety and patient outcomes data ... with a reduction in monthly migraine headache days among ...
(Date:4/20/2017)... ... April 20, 2017 , ... NetDimensions appoints Bill Mastin, a learning technology ... years of experience in the learning technologies industry, Mastin joins NetDimensions from the New ... Group plc (LTG). At LEO, Mastin served as SVP of the North America offices ...
(Date:4/20/2017)... ... ... Parallel6™ , the leader in mClinical™ technologies for improving patient enrollment, ... of the 2017 Top 10 eClinical Trial Management Solution Providers by Pharma Tech ... take pride in honoring Parallel6 as one of the top 10 companies that are ...
(Date:4/20/2017)... N.J. and PETACH TIKVAH, Israel ... BCLI), a leading developer of adult stem cell technologies for ... Executive Officer, will present at the Alliance for Regenerative Medicine,s ... Day on Thursday, April 27, 2017 at 09:40 EDT in ... Ralph Kern , MD, MHSc, Chief Medical Officer & ...
Breaking Biology Technology:
Cached News: